OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis

✍ Scribed by Haiming Ding; Chunhua Han; Dongmei Guo; Dasheng Wang; Ching-Shih Chen; Steven M. D'Ambrosio

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: French
• Weight: 529 KB
• Volume: 123
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.23896

✦ Synopsis

Abstract

OSU03012, a Celecoxib derivative, has been shown to inhibit proliferation and induce apoptosis in human cancer cell lines. However, its underlying mechanisms are not completely understood. In our study, the relationship between cell cycle inhibition and apoptosis induced by OSU03012 was investigated in human oral cancer cell lines. In the premalignant and malignant cell lines, OSU03012‐induced growth inhibition, S‐phase arrest, and apoptosis were accompanied by a marked increase in the activity of Erk1/2 and Cdk2/cyclin A. Inhibition of Cdks by roscovitine partially blocked OSU03012‐induced growth inhibition and apoptosis. Although the activity of cdc2/cyclin B was reduced, expression of constructively active cdc2AF did not reverse OSU03012‐induced S‐phase arrest. When Erk1/2 was inhibited by U0126 before addition of OSU03012, growth inhibition and apoptosis induced by OSU03012 were attenuated. The levels of the Cdk2/cyclin A were reduced and cells accumulated in the G~0~/G~1~ phase. When cells were allowed to accumulate in S‐phase before addition of U0126, apoptosis also was attenuated suggesting that Erk1/2 is required for both progression of cells into the S‐phase and apoptosis. Expression of constructively active MEK enhanced OSU03012‐induced apoptosis. OSU03012 selectively inhibited the proliferation in premalignant and malignant, but not normal human oral cell lines. In conclusion, we show that OSU03012 has potent anti‐proliferative and apoptotic activity against premalignant and malignant human oral cells through activation of Erk1/2, and Cdks. OSU0312 may provide unique opportunities for cancer prevention and sensitization of cancer cells to S‐phase modalities. © 2008 Wiley‐Liss, Inc.